Lifesci Capital Upgrades Inhibikase Therapeutics (NASDAQ:IKT) to Strong-Buy

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Inhibikase Therapeutics to a “sell” rating in a report on Saturday, December 27th. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research note on Tuesday, December 2nd. Finally, HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Friday, December 26th. Three equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy”.

Inhibikase Therapeutics Trading Up 13.9%

NASDAQ:IKT opened at $2.05 on Monday. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $2.58. The firm has a market cap of $154.11 million, a PE ratio of -5.26 and a beta of 0.84. The business’s 50-day simple moving average is $1.73.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.